Trials / Completed
CompletedNCT02261636
Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (actual)
- Sponsor
- Ferring Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
For both induction of remission and in maintenance of remission, different doses and treatment durations are used in practice. The aim of this study is to assess how mesalazine is used in clinical practice, at which doses and for how long and how these differences impact the patient disease state and work productivity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | mesalazine |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2019-01-14
- Completion
- 2019-01-14
- First posted
- 2014-10-10
- Last updated
- 2022-05-20
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02261636. Inclusion in this directory is not an endorsement.